Biorelevant characterization system for subcutaneous injections
ID: SSN_CDER-2025-126738Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONFDA OFFICE OF ACQ GRANT SVCSBeltsville, MD, 20705, USA

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

PSC

LABORATORY EQUIPMENT AND SUPPLIES (6640)

Original Source

https://sam.gov/opp/10e258ff3d2e4611adf907f893c344a7/view
Timeline
  1. 1
    Posted Apr 7, 2025, 12:00 AM UTC
  2. 2
    Updated Apr 7, 2025, 12:00 AM UTC
  3. 3
    Due Apr 18, 2025, 4:00 PM UTC
Description

The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking vendors to provide a Biorelevant Characterization System for evaluating subcutaneous drug formulations. This system is intended to enhance the capabilities of the Center for Drug Evaluation and Research (CDER) by enabling the investigation of drug release performance under simulated physiological conditions, utilizing integrated sensors and automated operation for unattended assessments. The initiative underscores the FDA's commitment to ensuring the quality, safety, and efficacy of pharmaceutical products while promoting innovation and domestic manufacturing. Interested parties, particularly small businesses under NAICS Code 334516, are encouraged to submit their qualifications by contacting Erika Crawford at erika.crawford@fda.hhs.gov or Maria Finan at maria.finan@fda.hhs.gov, as this is a Sources Sought Notice for market research purposes only, with no contract to be awarded at this stage.

Point(s) of Contact
Erika Crawford
(301) 796-0298
erika.crawford@fda.hhs.gov
Files
Title
Posted
SSN_CDER-2025-126738_FINAL.pdf
Apr 7, 2025, 5:04 PM UTC
The FDA's Office of Acquisitions and Grants Services (OAGS) has issued a Sources Sought Notice for market research regarding a Biorelevant Characterization System aimed at enhancing the Center for Drug Evaluation and Research (CDER) capabilities. The FDA invites responses from all businesses, especially small enterprises, to seek vendors that can supply the specified system for evaluating subcutaneous drug formulations. Key requirements include a system with integrated sensors, automated operation, and the ability to conduct multiple independent assays in a simulated extracellular matrix environment. The notice includes detailed technical specifications such as system components, performance metrics, and post-warranty maintenance options. Additionally, all submissions must include specific company information and adhere to privacy protocols, as responses will be used to assess qualifications but are not considered formal proposals. This initiative is part of the FDA's ongoing commitment to ensuring the quality and efficacy of pharmaceutical products while promoting innovation and domestic manufacturing capabilities.
Lifecycle
Title
Type
Biorelevant characterization system for subcutaneous injections
Currently viewing
Sources Sought
Similar Opportunities
IDIQ for the purchase of human induced pluripotent stem cell-derived cells
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking to award a sole-source contract for the procurement of human induced pluripotent stem cell-derived cells from Fujifilm Cellular Dynamics. This acquisition aims to support a research program focused on microphysiological systems (MPS), which are critical for advanced in-vitro models used in drug safety and efficacy assessments. The cells, including cardiomyocytes, neurons, astrocytes, and hepatocytes, will be cryopreserved and utilized by FDA scientists at the Center for Drug Evaluation and Research, ensuring continuity in ongoing projects due to the established partnership with Fujifilm. Interested vendors may submit capability statements within 15 days of the notice, with the response deadline set for 10 AM EST on May 2, 2025; inquiries should be directed to Telisha Wilson at telisha.wilson@fda.hhs.gov.
Purchase of FY25 Nanion Consumables
Buyer not available
The U.S. Food and Drug Administration (FDA) is seeking quotations for the purchase of Nanion consumables to support ion channel pharmacology experiments using the SyncroPatch 384 automated patch clamp system. This procurement aims to facilitate research on drug effects on ion channels, which is crucial for understanding drug safety and efficacy, with a contract duration of 12 months and the possibility of a 12-month extension. The selected contractor will be responsible for delivering consumables in four separate batches throughout the year, ensuring compliance with federal contracting regulations. Interested parties should direct their inquiries to Freshta Javid or L. Maria Finan by April 17, 2025, at 12:00 PM ET, and must adhere to the total small business set-aside requirements under NAICS code 334516.
Research and Development of the FDA ARGOS System
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified vendors for the research and development of the FDA ARGOS System, as outlined in a Sources Sought Notice. The primary objective is to enhance the FDA ARGOS database and develop bioinformatics and artificial intelligence tools to analyze genetic data, thereby improving public health preparedness and regulatory processes related to medical countermeasures against infectious diseases. This initiative is crucial for advancing diagnostic capabilities through Next Generation Sequencing (NGS) technology, which can identify microbial pathogens efficiently and accurately. Interested parties must submit their responses, including a Vendor Feedback Form, to Nicholas Bisher and Kimberly Pennix by May 2, 2025, at 2:00 PM EST, as no solicitation is currently available.
Nfusion Subscription Service (or equal)
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking sources for the Nfusion Annual Subscription Service, which includes geo site access, either as a brand name or an equivalent product. The primary objective is to procure 25 concurrent licenses for Nfusion to enable up to 175 investigators to conduct secure and anonymous online research, which is critical for the FDA's Office of Criminal Investigations in enforcing laws related to FDA-regulated products. The service must meet specific cybersecurity requirements, including malware immunity and compatibility with FDA IT systems, while also providing maintenance and technical support throughout the contract duration. Interested parties are encouraged to submit capability statements by April 25, 2025, and should direct any inquiries to Robert Waite at robert.waite@fda.hhs.gov.
PRIMO Software Licensing
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide PRIMO Software Licensing and Maintenance Support Services. The procurement involves supplying 21 PRIMO software licenses for a base year, with two additional option years, to ensure the continuous operation of the FDA's CFSAN CAEMS system. This software is crucial for pharmacovigilance and regulatory compliance, enhancing the FDA's capabilities in monitoring food safety. Interested parties must submit their quotes by August 26, 2024, and are encouraged to contact Roosevelt Walker at roosevelt.walker@fda.hhs.gov for further details. The contract will be awarded as a firm-fixed-price purchase order, emphasizing compliance with federal acquisition regulations and accessibility standards.
FINIA 2.0 Fill Finish Equipment – Terumo BCT, Inc
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Terumo BCT, Inc. for the procurement of one FINIA 2.0 Fill Finish Equipment unit. This equipment is critical for the preparation and cryopreservation of cellular therapy doses, addressing risks associated with manual processes that could lead to inadequate dosing and severe side effects. The FINIA 2.0 device is uniquely designed to handle volumes from 2 mL to 100 mL while complying with current Good Manufacturing Practices (cGMP), making it essential for the NIH's new Center for Cellular Engineering facilities in Bethesda, Maryland. Interested parties may submit capability statements to Damien Goines at damien.goines@nih.gov by May 5, 2025, at 9:00 AM (EST).
Illumina MiSeq Instrument Service Agreement
Buyer not available
The U.S. Food and Drug Administration (FDA) is conducting market research to identify small business sources capable of providing a service agreement for the Illumina MiSeq instrument, which is essential for the National Center for Toxicological Research (NCTR). The procurement involves a preventative maintenance and corrective maintenance service agreement, including scheduled on-site visits, unlimited technical support, and adherence to OEM specifications. This service is critical for ensuring the reliability of ongoing research at the NCTR facility in Jefferson, Arkansas. Interested parties must submit their capability statements by April 30, 2025, to Nick Sartain at nick.sartain@fda.hhs.gov, referencing NCTR-2025-128267.
Ambr 250 High Throughput Bioreactor System
Buyer not available
The Department of Defense, through the Defense Health Agency, is seeking to procure an Ambr 250 High Throughput Bioreactor System for the Pilot Bioproduction Facility at the Walter Reed Army Institute of Research in Silver Spring, Maryland. This procurement aims to enhance capabilities for monoclonal antibody production, allowing for simultaneous testing of multiple conditions to accelerate the manufacturing of vaccines and biologics for military-relevant infectious diseases. The system must meet specific Minimum Essential Characteristics, including the ability to process up to 12 cultures, automated controls for critical parameters, and compliance with FDA regulations, particularly 21 CFR Part 11 for data integrity. Interested vendors should note that the anticipated solicitation release is on April 10, 2025, with a contract performance period from June 1, 2025, to May 31, 2029. For further inquiries, contact Ms. Brenda Mena at brenda.i.mena.civ@health.mil or Ms. Sharew Hailu at sharew.hailu.civ@health.mil.
Jefferson Laboratories On-Site Laboratory Equipment Maintenance, Repair, and Fabrication Services
Buyer not available
The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking proposals for on-site laboratory equipment maintenance, repair, and fabrication services at the National Center for Toxicological Research (NCTR) in Jefferson, Arkansas. The selected contractor will be responsible for maintaining and repairing a variety of laboratory instruments, ensuring compliance with safety protocols and standard operating procedures, while also providing preventive maintenance and specialized equipment design services. This contract is crucial for supporting ongoing toxicological research, as much of the equipment requires maintenance beyond manufacturer warranties. Interested parties should submit their proposals, adhering to the instructions and evaluation criteria outlined in the solicitation, with inquiries directed to Suzanne Martella at suzanne.martella@fda.hhs.gov or by phone at 870-543-7540. The contract will be awarded as a firm fixed-price agreement covering a base year and four option years, with detailed requirements specified in the solicitation documents.
Q--T-Cell Manufacturing for Protocol 18-H-0012
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking contractors for T-Cell Manufacturing related to Protocol 18-H-0012. This procurement aims to fulfill the requirements for biological product manufacturing, which is crucial for advancing medical research and therapeutic applications. The contract falls under the NAICS code 325414, focusing on biological product manufacturing, and is categorized under medical laboratory testing services. Interested parties can reach out to Noelle Decenzo at noelle.decenzo@nih.gov or call +1 301 402 5571 for further details regarding this presolicitation opportunity.